Lung cancer drug combo trial halted midway
Disease control
Terminated
This study tested a new drug called nogapendekin alfa inbakicept combined with standard treatments for people with advanced non-small cell lung cancer. The goal was to see if the combination could slow cancer growth or improve survival. The trial was stopped early, and results ar…
Phase: PHASE3 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Apr 26, 2026 20:01 UTC